Singlet Oxygen‐Versus Nonsinglet Oxygen‐Mediated Mechanisms of Sensitizer Photobleaching and Their Effects on Photodynamic Dosimetry

We report the effects of singlet oxygen (1O2) and non‐1O2‐mediated sensitizer photobleaching on oxygen consumption and dosimetry during photodynamic therapy (PDT) of sensitized multicell tumor spheroids. We develop a theoretical model for the description of non‐1O2‐mediated photobleaching resulting from irreversible reactions of the excited singlet or triplet sensitizer populations with cell substrate. We show that the fluence‐dependent simple exponential decay expression of sensitizer degradation is not consistent with these mechanisms and, therefore, with any reasonable mechanism that we consider, because we have shown previously that 1O2‐mediated photobleaching cannot be described by a simple exponential with a constant photobleaching coefficient (I. Georgakoudi et al., Photochem. Photobiol. 65, 135–144, 1997). Analysis of oxygen microelectrode measurements performed at the edge of Nile blue selenium (EtNBSe)‐and protoporphyrin IX (PpIX)‐sensitized spheroids during PDT demonstrates that the former drug photobleaches via a non‐1O2‐mediated mechanism, while the latter is degraded via a 1O2‐mediated mechanism. Comparisons of the cytotoxic effects of EtNBSe with those of Photofrin® (a drug that is degraded via a 1O2‐mediated mechanism) indicate that the lower threshold 1O2 dose and the higher extinction coefficient and 1O2 yield for EtNBSe do not necessarily result in improved photodynamic effects, thus emphasizing the importance of the sensitizer photo‐bleaching mechanism for dosimetry.

[1]  L. Grossweiner.  PDT light dosimetry revisited. , 1997, Journal of photochemistry and photobiology. B, Biology.

[2]  W R Greco,et al.  Lack of reciprocity in drug and light dose dependence of photodynamic therapy of pancreatic adenocarcinoma in vitro. , 1995, Cancer research.

[3]  G. Wagnières,et al.  Clinical pharmacokinetic studies of photofrin by fluorescence spectroscopy in the oral cavity, the esophagus, and the bronchi , 1995, Cancer.

[4]  K. Berg,et al.  EVALUATION OF SULFONATED ALUMINUM PHTHALOCYANINES FOR USE IN PHOTOCHEMOTHERAPY. A STUDY ON THE RELATIVE EFFICIENCIES OF PHOTOINACTIVATION , 1989, Photochemistry and photobiology.

[5]  Thomas H. Foster,et al.  Microelectrode measurements of photochemical oxygen depletion in multicell tumor spheroids during photodynamic therapy , 1994, Photonics West - Lasers and Applications in Science and Engineering.

[6]  M W Berns,et al.  Dosimetry model for photodynamic therapy with topically administered photosensitizers , 1996, Lasers in surgery and medicine.

[7]  P. Monnier,et al.  Optimizing light dosimetry in photodynamic therapy of early stage carcinomas of the esophagus using fluorescence spectroscopy , 1996, Lasers in surgery and medicine.

[8]  Kristian Berg,et al.  Photobleaching of protoporphyrin IX in cells incubated with 5‐aminolevulinic acid , 1997, International journal of cancer.

[9]  J. Moan,et al.  On the diffusion length of singlet oxygen in cells and tissues , 1990 .

[10]  Hubert van den Bergh,et al.  In-vivo measurement of fluorescence bleaching of meso-tetra hydroxy phenyl chlorin (mTHPC) in the esophagus and the oral cavity , 1995, European Conference on Biomedical Optics.

[11]  L. Bezdetnaya,et al.  Spectroscopic and Biological Testing of Photobleaching of Porphyrins in Solutions * , 1996, Photochemistry and photobiology.

[12]  T. Mukherjee,et al.  Triplet excited states and semiquinone radicals of 1,4-disubstituted anthraquinones , 1990 .

[13]  J Moan,et al.  Effect of bleaching of porphyrin sensitizers during photodynamic therapy. , 1986, Cancer letters.

[14]  M G Nichols,et al.  Oxygen diffusion and reaction kinetics in the photodynamic therapy of multicell tumour spheroids. , 1994, Physics in medicine and biology.

[15]  J Moan,et al.  PHOTOBLEACHING OF PORPHYRINS USED IN PHOTODYNAMIC THERAPY AND IMPLICATIONS FOR THERAPY , 1987, Photochemistry and photobiology.

[16]  R. Steiner,et al.  Dynamic fluorescence changes during photodynamic therapy in vivo and in vitro of hydrophilic A1(III) phthalocyanine tetrasulphonate and lipophilic Zn(II) phthalocyanine administered in liposomes. , 1996, Journal of photochemistry and photobiology. B, Biology.

[17]  H. S. de Bruijn,et al.  Photobleaching during and re‐appearance after photodynamic therapy of topical ALA‐induced fluorescence in UVB‐treated mouse skin , 1997, International journal of cancer.

[18]  Dominic J. Robinson,et al.  In vivo monitoring of photosensitizer fluorescence during photodynamic therapy , 1995, Other Conferences.

[19]  W. Star,et al.  In vivo fluorescence kinetics and photodynamic therapy using 5-aminolaevulinic acid-induced porphyrin: increased damage after multiple irradiations. , 1994, British Journal of Cancer.

[20]  William R. Potter,et al.  The Theory Of Photodynamic Therapy Dosimetry: Consequences Of Photodestruction Of Sensitizer , 1987, Other Conferences.

[21]  Stanley B. Brown,et al.  The Subcellular Localization of Zn(ll) Phthalocyanines and Their Redistribution on Exposure to Light , 1997, Photochemistry and photobiology.

[22]  M G Nichols,et al.  Fluence rate effects in photodynamic therapy of multicell tumor spheroids. , 1993, Cancer research.

[23]  Thomas S. Mang,et al.  THE THEORY OF PHOTODYNAMIC THERAPY DOSIMETRY: CONSEQUENCES OF PHOTO‐DESTRUCTION OF SENSITIZER , 1987 .

[24]  T. Mang,et al.  PHOTODYNAMIC THERAPY IN THE TREATMENT OF PANCREATIC CARCINOMA: DIHEMATOPORPHYRIN ETHER UPTAKE and PHOTOBLEACHING KINETICS , 1987, Photochemistry and photobiology.

[25]  W. Potter,et al.  PHOTOBLEACHING OF PHOTOFRIN II AS A MEANS OF ELIMINATING SKIN PHOTOSENSITIVITY * , 1987, Photochemistry and photobiology.

[26]  M G Nichols,et al.  The Mechanism of Photofrin Photobleaching and Its Consequences for Photodynamic Dosimetry , 1997, Photochemistry and photobiology.

[27]  J. Spikes.  QUANTUM YIELDS AND KINETICS OF THE PHOTOBLEACHING OF HEMATOPORPHYRIN, PHOTOFRIN II, TETRA(4‐SULFONATOPHENYL)‐PORPHINE AND UROPORPHYRIN , 1984 .

[28]  J Moan,et al.  LIGHT INDUCED RELOCALIZATION OF SULFONATED meso‐TETRAPHENYLPORPHINES IN NHIK 3025 CELLS AND EFFECTS OF DOSE FRACTIONATION , 1991, Photochemistry and photobiology.

[29]  A. Cincotta,et al.  Phototoxicity, redox behavior, and pharmacokinetics of benzophenoxazine analogues in EMT-6 murine sarcoma cells. , 1993, Cancer research.

[30]  K. Berg,et al.  THE PHOTODEGRADATION OF PORPHYRINS IN CELLS CAN BE USED TO ESTIMATE THE LIFETIME OF SINGLET OXYGEN , 1991, Photochemistry and photobiology.

[31]  Leonard I. Grossweiner,et al.  The Science of Phototherapy , 1994 .

[32]  B. Tromberg,et al.  In vivo TUMOR OXYGEN TENSION MEASUREMENTS FOR THE EVALUATION OF THE EFFICIENCY OF PHOTODYNAMIC THERAPY , 1990, Photochemistry and photobiology.

[33]  T. Foster,et al.  Effects of the Subcellular Redistribution of Two Nile Blue Derivatives on Photodynamic Oxygen Consumption , 1998, Photochemistry and photobiology.

[34]  J. Moan,et al.  PHOTOINDUCED DEGRADATION AND MODIFICATION OF PHOTOFRIN II IN CELLS in vitro , 1988, Photochemistry and photobiology.

[35]  William R. Crum,et al.  Rate-equation analysis of Protoporphyrin IX photo-oxidation , 1996, European Conference on Biomedical Optics.

[36]  Marianne Krieg,et al.  Self-sensitized photo-oxidation of protoporphyrin IX and related porphyrins in erythrocyte ghosts and microemulsions: A novel photo-oxidation pathway involving singlet oxygen , 1984 .

[37]  R. Anderson,et al.  Iontophoretic delivery of ALA provides a quantitative model for ALA pharmacokinetics and PpIX phototoxicity in human skin. , 1997, The Journal of investigative dermatology.

[38]  Giedre Streckyte,et al.  Phototransformations of sensitizers 1. Significance of the nature of the sensitizer in the photobleaching process and photoproduct formation in aqueous solution , 1997 .